Clinical Investigation Core (CIC) will be established to serve the needs of all of the members of the NCCFAR. This core will advise users of trial design, prepare research protocols, assist in Investigational Review Board (IRB) and regulatory submission, conduct clinical research related to HIV and related infections, and keep all records needed in the performance of Good Clinical Practice (GCP). The CIC will be open to all members of the NCCFAR, and will be located with the NCCFAR at the Center for Aids Research, Education, and Services in Sacramento, California. The CIC will support all relevant research projects whose focus are on HIV-1 or related infections. The specific emphasis areas of the CIC have been determined to be those that will maximize the research activities of the probable users, both established and junior faculty. These will be to: A. Conduct trials that will evaluate HIV-1 vaccines, and to test vaccine concepts using novel adjuvants, vectors, or delivery systems; B. Conduct studies on immune response function and immunologic restoration during HIV-1 infection; C. Assess virologic correlates of disease progression; D. Study and improve outreach to patient populations and health care providers, especially minority, migrants, and the rural populations; E. Perform health services research to study the effectiveness and cost-benefit of our care and interventions; F. Foster studies in HIV-1 and STD prevention research, including prevention of the related conditions that may increase high-risk behavior, such as injecting drug use; G. Conduct studies in infections, malignancies, or other conditions related to HIV-1 infection or therapy; H. Foster mentoring of junior and foreign investigators; and I. Assist in pharmacologic studies of HIV therapies.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Davis
United States
Zip Code
Sena, Angela A S; Glavan, Tiffany; Jiang, Guochun et al. (2016) Divergent Annexin A1 expression in periphery and gut is associated with systemic immune activation and impaired gut immune response during SIV infection. Sci Rep 6:31157
Dubie, Robert A; Maksaereekul, Saipiroon; Shacklett, Barbara L et al. (2009) Co-immunization with IL-15 enhances cellular immune responses induced by a vif-deleted simian immunodeficiency virus proviral DNA vaccine and confers partial protection against vaginal challenge with SIVmac251. Virology 386:109-21
Asmuth, D M; Abel, K; George, M D et al. (2008) Pegylated interferon-alpha 2a treatment of chronic SIV-infected macaques. J Med Primatol 37:26-30
George, M D; Verhoeven, D; McBride, Z et al. (2006) Gene expression profiling of gut mucosa and mesenteric lymph nodes in simian immunodeficiency virus-infected macaques with divergent disease course. J Med Primatol 35:261-9
Kuekrek, Haydar; Schlingmann, Tobias; Valdez, Hernan et al. (2005) Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individuals. AIDS 19:1967-74
Israel-Ballard, Kiersten; Chantry, Caroline; Dewey, Kathryn et al. (2005) Viral, nutritional, and bacterial safety of flash-heated and pretoria-pasteurized breast milk to prevent mother-to-child transmission of HIV in resource-poor countries: a pilot study. J Acquir Immune Defic Syndr 40:175-81
Sankaran, Sumathi; Guadalupe, Moraima; Reay, Elizabeth et al. (2005) Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors. Proc Natl Acad Sci U S A 102:9860-5
George, Michael D; Reay, Elizabeth; Sankaran, Sumathi et al. (2005) Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4+ T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration. J Virol 79:2709-19